HELIOS- A:A Study to Evaluate the Efficacy and Safety of ALN-TTRSC02 in Patients with Hereditary Transthyretin Amyloidosis (hATTR Amyloidosis)
Not Recruiting
18-85 years
All
Phase
3
164 participants needed
1 Location
Brief description of study
The purpose of this study is to evaluate the efficacy and safety of vutrisiran (ALN-TTRSC02) in patients with hereditary transthyretin amyloidosis (hATTR amyloidosis). Participants will receive vutrisiran or the reference comparator patisiran during the Treatment Period.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Hereditary Transthyretin Amyloidosis,hATTR Amyloidosis
-
Age: Between 18 Years - 85 Years
-
Gender: All
Male or female ; 18 to 85 years of age ; Has a diagnosis of hATTR amyloidosis with transthyretin (TTR) mutation;
Updated on
11 Sep 2024.
Study ID: 832041
